A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
- To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of
SAR245408 administered in combination with SAR256212 in adult patients with locally
advanced or metastatic solid tumors.
Secondary Objectives:
- To characterize the global safety profile of SAR245408 in combination with SAR256212
- To evaluate the pharmacokinetic (PK) profile of SAR245408 and SAR256212 used in
combination
- To evaluate the objective response rate (ORR) and tumor volume change (for expansion
cohort only)
- To determine the immunogenicity of SAR256212 as administered with SAR245408